Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2016 Archives
--Company Reports Record Net Sales of $164 Million, Adjusted Operating Income of $65 Million; Continues to Expect its Fourth Quarter to Be In Line with Previous Outlook-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 third quarter and nine months ended March 31, 2016. As previously announced, the company completed the... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2016 third quarter on Tuesday, May 3, 2016 after the market closes. Lannett management will... More |
--Lannett Has Exclusive U.S. Marketing Rights to Insulin Product; Fifth Project with Strategic Partner-- Lannett Company, Inc. (NYSE: LCI) today announced plans to co-develop a generic insulin pharmaceutical product for the U.S. market with its strategic partner in China, YiChang HEC ChangJiang... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its president, Michael J. Bogda, is leaving the company, effective June 3, 2016, to pursue other interests. "Mike spearheaded the integration... More |
--Company Expects to Launch Temolozomide Capsules Shortly-- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Potassium... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has revised its fiscal 2016 full-year guidance. "We are pleased to see that shareholders have renewed confidence in our company," said... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Kremers Urban Pharmaceuticals Inc. (KU), and a key customer are in the process of re-establishing business... More |
Lannett Company, Inc. (NYSE: LCI) today announced that, as others in its industry have recently reported, it is experiencing unanticipated market softness. As a result, the company is reviewing... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the following investor conferences: Raymond James & Associates' 37th Annual Institutional Investors Conference on... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Kremers Urban Pharmaceuticals Inc. (KU), has received approval from the U.S. Food and Drug Administration (FDA)... More |
--Net Sales of $127 Million, GAAP EPS of $0.36, Adjusted EPS of $0.95; Company Reiterates Guidance for Fiscal 2016 Full Year-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 second quarter and first six months ended December 31, 2015. As previously announced, the company completed... More |
--Initiatives Designed to Streamline Operations, Improve Efficiencies and Significantly Reduce Costs-- Lannett Company, Inc. (NYSE: LCI) today announced a number of restructuring actions (the Plan) to streamline operations, improve efficiencies and significantly reduce costs. The initiatives are... More |
--Net Sales of Approximately $127 Million, GAAP EPS of $0.33 to $0.36, Adjusted EPS of $0.93 to $0.95; Company to Report Full Financial Results, Host Conference Call on February 3-- Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2016 second quarter net sales of approximately $127 million, GAAP earnings per diluted share of $0.33 to $0.36... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report preliminary fiscal 2016 second-quarter financial results, provide full-year guidance and host a related conference call on... More |
| 1-25 26-40 |